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Abstract
Cholestasis results from hepatocyte dysfunction due to the accumulation of bile acids in the cell, many of which are
known to be cytotoxic. Recent evidence implicates competitive antagonism of key cytotoxic responses as the
mechanism by which certain therapeutic bile acids might afford cytoprotection against cholestasis. In this work, we
compare the relative cytotoxicity of bile acids in terms of dose- and time-dependence. To better elucidate the
controversy related to the therapeutic use of ursodeoxycholate (UDCA) in cholestatic patients, we also evaluated the
effects of bile acid combinations. Viability of Wistar rat hepatocytes in primary culture was measured by LDH
leakage after 12 and 24 h exposure of cells to the various bile acids. All unconjugated bile acids caused a
dose-dependent decrease in cell viability. The tauro- and glyco-conjugates of chenodeoxycholate (CDCA) and UDCA
were all less toxic than the corresponding unconjugated form. Although relatively non-toxic, UDCA caused
synergistic cell killing by lithocholate (LCA), CDCA, glyco-CDCA (GCDC) and tauro-CDCA (TCDC). Glycour-
sodeoxycholate decreased the toxicity of GCDC, but potentiated the toxicity of unconjugated CDCA and LCA. The
tauro-conjugate of UDCA had no significant effect. These data suggest that at cholestatic concentrations, bile
acid-induced cell death correlates with the degree of lipophilicity of individual bile acids. However, these results
indicate that the reported improvement of biochemical parameters in cholestatic patients treated with UDCA is not
due to a direct effect of UDCA on hepatocyte viability. Therefore, any therapeutic effect of UDCA must be
secondary to some other process, such as altered membrane transport or nonparenchymal cell function. © 2002
Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
Bile acids are sterol-derived, potentially cyto-
toxic compounds synthesized and secreted by hep-
atic epithelial cells into the bile canaliculus (Plaa
et al., 1982). During cholestasis (an impairment in
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bile flow) bile acids accumulate in the hepatocyte
(Greim et al., 1972). This accumulation of cyto-
toxic bile acids is thought to cause hepatocyte
necrosis contributing to the pathogenesis of the
cholestatic disease process and the development of
liver cirrhosis and liver failure (Kaplan, 1994).
Mechanisms implicated in the toxicity of bile acids
include stimulation of lipid peroxidation (Sokol et
al., 1993) and induction of mitochondrial dysfunc-
tion (Schaffner et al., 1971; Krahenbuhl et al.,
1992; Gores et al., 1998; Rolo et al., 2000).
Due to their membrane-active, detergent-like
properties, the cytotoxicity of bile acids has been
associated with the degree of lipophilicity of the
different molecular species (Scholmerich et al.,
1984; Delzenne et al., 1992). Ursodeoxycholate
(UDCA) is more hydrophilic than the primary,
dihydroxy bile acid chenodeoxycholate (CDCA).
Lithocholate (LCA), a secondary monohydroxy-
lated bile acid, is the most lipophilic of all bile
acids (Sarbu et al., 2001). In humans, bile acids
are conjugated to glycine and taurine, with the
glycine conjugates predominating (Hofmann,
1984). Conjugation decreases the lipophilicity and
renders the bile acids less cytotoxic (Sarbu et al.,
2001).
Not all bile acids are cytotoxic and minor
changes in bile acid structure can markedly alter
the biological activity (Scholmerich et al., 1984).
CDCA is the toxic bile acid most widely impli-
cated in cholestatic liver injury (Greim et al.,
1972). In contrast, UDCA (the -epimer of
CDCA) has been shown to reduce serum liver
enzymes in chronic liver diseases, although not in
all patients (Poupon et al., 1994). Ursodeoxycholic
acid (UDCA) is considered to be an effective
treatment for primary biliary cirrhosis and other
cholestatic liver diseases in humans (Beuers et al.,
1998), such as intrahepatic cholestasis of preg-
nancy. Serum liver tests and histopathological
suggest improvement of liver function in patients
treated with UDCA. In most of the cases, UDCA
shows a favorable effect on biochemical indices
(van Hoogstraten et al., 1999) but not on symp-
toms or the progression of histological stage (Neu-
berger, 2000). Indeed, the recent report by
Neuberger ‘URSO—panacea or placebo?’ draws
attention to the necessity to re-examine the thera-
peutic benefit of UDCA.
The nature of this apparent cytoprotection is
still unclear. Although some studies reported bile
acids effects on cell viability (Delzenne et al., 1992;
Spivey et al., 1993; Hillaire et al., 1995), no sys-
tematic study has been carried out. With growing
debate regarding the effectiveness of UDCA and
conjugates in patients with cholestasis, several
important questions are raised, one of which is
whether the observed effects of UDCA in vivo are
related to a direct effect at the hepatocyte level. In
order to address this question, we evaluated the
effects of UDCA and conjugates on hepatocyte
cell viability, either alone or in combination with
other bile acids.
2. Materials and methods
2.1. Materials
UDCA, LCA, glycoursodeoxycholate (GUDC),
CDCA and conjugates, were purchased from
Sigma Chemical Co. (St. Louis, MO). Taurour-
sodeoxycholate (TUDC), as sodium salt, was ob-
tained from Cal Biochem (La Jolla, CA). UDCA
and LCA were dissolved in ethanol, all others in
water. Lactate dehydrogenase (LDH) was pur-
chased from Sigma and Collagenase type 2 was
from Worthington (Freehold, NJ). All other
chemicals were of analytical grade and obtained
from the standard commercial sources. A Labsys-
tems type 374 plate-reader was used for all mea-
surements of fluorescence intensity.
2.2. Animals
Male Sprague–Dawley rats (Harlan Laborato-
ries, Madison, WI) weighing 1986 g were main-
tained in AAALAC-accredited, climate-controlled
facilities and allowed free access to food (Purina
Chow) and water.
2.3. Rat hepatocyte isolation and maintenance in
cell culture
Hepatocytes were isolated according to a
modified procedure of Seglen (1976). The main
alterations were that perfusion of the liver with
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collagenase was performed in situ and after diges-
tion, cells were dispersed in RPMI growth
medium. Cells were plated on 12-well plates at a
density of 0.6×106 cells per well. Culture medium
was Rosewell Park Memorial Institute (RPMI)
medium supplemented with 5% fetal bovine
serum, 1 M insulin, 100 M hydrocortisone
sodium succinate, gentamicin (50 mg/ml) and 15
mM HEPES (pH 7.4). Cells were maintained in
an incubator at 37 °C, 5% CO2 and humidified
atmosphere. After allowing 2–3 h for the cells to
attach, medium was replaced and the cells left for
18–24 h. The culture medium was then replaced
and bile acids were added. Treatment was carried
out under the same incubation conditions for up
to 24 h.
2.4. Cell iability assay
Cell viability was determined fluorometrically
by estimating release of LDH into media (Moran
and Schnellmann, 1996). The determination of
LDH activity is based on the reduction of pyru-
vate to lactate, as monitored by the decrease in
NADH fluorescence at 450 nm wavelength with
excitation wavelength 355 nm. Fresh reaction so-
lution was made by mixing 0.4 ml of 16.2 mM
pyruvate with 10 ml of 0.2 mM NADH in phos-
phate buffer (pH 7.5). After incubation of hepato-
cytes with bile acids for 12 or 24 h, 5 l of the
cell-free supernatant was added to 200 l of fresh
assay solution to initiate the reaction. Total cellu-
lar LDH was determined by lysing the cells after
freezing in a solution of 0.1 M sodium phosphate
buffer (pH 7.0) The amount of LDH released into
the media was expressed as a percentage of total
LDH. Using this method, control cell viability
was 72.19.2% after 24 h of incubation.
2.5. Statistical analysis
All data are expressed as the meanS.E.M. for
three to four independent experiments. Statistical
evaluation was performed using the two-tailed
paired Student’s t-test. A P value 0.05 was
considered statistically significant.
3. Results and discussion
Bile acids are amphipathic, endogenous steroid
compounds that possess detergent properties,
which at high concentrations have deleterious ef-
fects upon cell membranes (Scholmerich et al.,
1984). However, at lower concentrations (50
M), bile acids may alter cell function by interfer-
ing with intracellular signaling mechanisms (Rust
et al., 2000) and mitochondrial membrane perme-
ability (Gores et al., 1998; Rolo et al., 2000).
Regardless, cholestasis due to accumulation of
bile acids has been thought to reflect the direct
cytotoxicity of the individual bile acids (Kaplan,
1994).
In the present work, cell viability was investi-
gated to assess the relative potency of bile acids
on rat hepatocytes in primary culture. The struc-
tures of the individual bile acids included in this
investigation are illustrated in Table 1. Cytotoxic-
ity of individual bile acids was both time and
concentration dependent and corresponded to
their lipophilic character. Upon 12 h of exposure,
a decrease in cell viability was observed most
dramatically for CDCA and LCA. Hepatocyte
viability at 12 h was 709% for 150 M CDCA,
Table 1
Relationship between bile acid structure and their polarity/
acidity versus lipophilicity (Sarbu et al., 2001)
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Fig. 1. Changes in cell viability following 24 h incubation with
different concentrations of bile acids. Cellular viability was
determined fluorometrically by estimating the release of LDH
into media. Total cellular LDH was determined after lysing
cells; the amount of LDH released into media at any given
time during the incubation was expressed as the percentage of
total LDH. Percent viability was obtained by comparing with
control cell viability, considered as 100%. Data represent the
meanS.E.M. of measurements from three separate animals.
*Values statistically different from control (P0.05).
cholate (GCDC) required higher concentrations
to cause a significant decrease in cell viability in
24 h (Fig. 1B, C). The fact that conjugation with
either glycine or taurine decreased cytotoxicity of
CDCA agrees with the observations made by
others (Scholmerich et al., 1984). In contrast,
Spivey et al. (1993) reported that at a concentra-
tion of 250 M, GCDC was more toxic than
either CDCA or TCDC. Significant differences in
the experimental procedure may explain the dis-
crepancy. For instance, Spivey et al. (1993)
worked with hepatocytes after only 2 h in culture.
Cell viability after 24 h exposure to the glyco-
and tauro-conjugated forms of UDCA was also
tested. Both glyco- (GUDC) and tauroursodeoxy-
cholate (TUDC) were found to have no signifi-
cant effect on LDH release (Fig. 1C), whereas
unconjugated UDCA at 500 M decreased cell
viability to 5810% control.
The next set of experiments was designed to
assess the putative hepatoprotective effects of
UDCA and derivatives against the cytotoxicity of
more lipophilic bile acids implicated in cholesta-
sis. Based on the results of the first set of experi-
ments, 250 M UDCA was selected as the
concentration for use in these studies (25% cell
killing after 24 h incubation). The non-toxic
tauro- and glycoursodeoxycholate were used at
500 M. Fig. 2(A,B) shows that co-incubation of
rat hepatocytes for 24 h in primary culture with
both UDCA and either 100 M LCA, 150 M
CDCA, 500 M GCDC or 500 M TCDC, re-
sulted in a significant increase in enzyme leakage
compared to the bile acids alone. These data
demonstrate that contrary to in vivo exposure,
there is no cytoprotection by UDCA against bile
acid-induced hepatocyte lethality in vitro. In fact,
UDCA synergized the cytotoxicity of all other
bile acids in hepatocyte cell culture. Similar results
were observed for 12 h co-incubations (data not
shown). Our results agree with those of Hillaire et
al. (1995) who reported concentration-dependent
increases in LDH leakage by CDCA (100–500
M) in human hepatocytes in primary culture.
Additionally, Hillaire et al. observed that TUDC
and UDCA (at the same concentrations used in
our study) did not have a protective effect when
added concomitantly with CDCA (Hillaire et al.,
599% for 150 M LCA and 7710% for 500
M taurochenodeoxycholate (TCDC). Exposure
to the lipophilic bile acids CDCA and LCA for 24
h resulted in a significant enzyme release even at
low concentrations (Fig. 1A), whereas hydrophilic
bile acids, UDCA, TCDC and glycochenodeoxy-
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1995). A report by Pazzi et al. (1997), however,
indicates that addition of UDCA significantly re-
duced the hepatotoxic effect of the lipophilic bile
acid, deoxycholate but not chenodeoxycholate.
These studies were made with freshly isolated rat
hepatocytes suspended on a resin column and
perfused with different concentrations of bile
acids (Pazzi et al., 1997). Galle et al. (1990) also
reported a decrease of toxicity of GCDC by
UDCA in primary human hepatocytes.
We also evaluated the potential for TUDC to
be cytoprotective in combination with cytotoxic
bile acids. In this case, TUDC was found to have
no significant effect on hepatocyte killing by
LCA, CDCA, GCDC or TCDC (Fig. 2A, B). In a
previous report, Heuman et al. (1991) described
that the hepatotoxicity of lipophilic bile acids was
reduced in the presence of TUDC. However, this
study was aimed at evaluating the immediate ef-
fects of therapeutic bile acids at the cellular level.
Primary monolayer cultures of adult rat hepato-
cytes were incubated for 1–240 min with varying
concentrations of the different bile acids (Heuman
et al., 1991). This contrasts with the much more
prolonged exposure of the present investigation.
GUDC elicited mixed effects on cell viability
when added concomitantly with the other bile
acids. Whereas GUDC did not alter the cytotoxic-
ity of TCDC (Fig. 2B), it was cytoprotective
against GCDC (Fig. 2B), but potentiated the cy-
totoxicity of both LCA and CDCA (Fig. 2A).
The differential effect of tauro- and glyco-con-
jugated bile acids may reflect slight differences in
physical–chemical properties. For example, ami-
dation is known to significantly reduce the cyto-
toxicity of the more lipophilic forms of
unconjugated bile acids, both in hepatocytes
(Scholmerich et al., 1984) and bile duct cells. As
such, the tauro-conjugated derivatives are less ef-
fective than the glyco-conjugated species. The ba-
sis for this distinction is not known and it may be
related to intracellular transport. Alternatively,
taurine- and glycine-conjugated forms may differ-
entially activate signaling cascades leading to the
activation or repression of specific mechanisms
controlling cell death and survival (Spivey et al.,
1993; Que et al., 1999; Rust et al., 2000).
In the present work, we observed a strong
correspondence between bile acid toxicity and
their degree of lipophilicity, the most important
feature concerning biological activity. A recent
report (Sarbu et al., 2001) concerning the
lipophilic character of bile acids and their tauro-
and glyco-conjugates showed that the main differ-
ence between the three subgroups of compounds
is their polarity and acidity (Table 1). Glyco-con-
Fig. 2. Cell viability after exposure to combinations of bile
acids: UDCA, GUDC or TUDC with LCA, CDCA, GCDC
or TCDC. Cellular viability was determined fluorometrically
by estimating the release of LDH into media. Total cellular
LDH was determined after lysing the cells; the amount of
LDH released into media at any given time during the incuba-
tion was expressed as the percentage of total LDH. Percent
viability was obtained by comparing with control cell viability,
considered as 100%. Data represent the meanS.E.M. of
measurements from four separate animals. *Values statistically
different when compared to cells exposed just to CDCA, LCA,
GCDC or TCDC (P0.05).
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jugates share many of the same properties as the
free bile acids. However, the tauro-conjugates are
more polar and acidic and thereby substantially
less lipophilic. This could explain the similar ac-
tivities of the unconjugated and glycine conju-
gated bile acids against hepatocyte cell killing, but
with dissimilar behavior of the taurine conjugates.
Although we can only speculate on a probable
explanation for the observed synergism, the
greater than additive effect of UDCA and the
potentiation of cell death by GUDC (when com-
bined with LCA, CDCA, GCDC and TCDC)
may reflect non-linear dose–response, whether it
be by a detergent/membrane damaging effect or
at level of cell signal/cell function.
UDCA is the only approved treatment for
chronic cholestatic liver disease, but its effects on
disease progression are not completely clarified. A
marked improvement in biochemical parameters
is frequently reported (van Hoogstraten et al.,
1999); however, this improvement is not reflected
in the overall rate of progression of histological
stage associated with chronic cholestatic liver dis-
ease or the clinical symptoms of the patients
(Neuberger, 2000). In order to provide new in-
sights into the understanding of the effects of
therapeutic bile acids, in vitro studies have been
done. Several reports described a role for the
putative beneficial effect of UDCA exerted at the
level of mitochondrial function, where UDCA
prevents the impairment of mitochondrial func-
tion induced by toxic bile acids (Gores et al.,
1998; Rodrigues et al., 1998). It has also been
reported that UDCA could exert a cytoprotective
action related to oxidative injury and antioxidant
systems (Mitsuyoshi et al., 1999). However, other
studies do not show cytoprotection by UDCA
against toxic bile acids at the level of mitochon-
dria or cell function (Krahenbuhl et al., 1994;
Hillaire et al., 1995; Rolo et al., 2000). The report
by Krahenbuhl et al. (1994) described that
UDCA, but not TUDC, decreased the toxicity of
lipophilic bile acids at the level of mitochondrial
electron transport chain, up to a concentration of
100 M. However, at higher concentrations,
UDCA increased bile acid-induced mitochondrial
toxicity (Krahenbuhl et al., 1994). Additionally,
our previous data (Rolo et al., 2000) also demon-
strated no role for UDCA in preventing mito-
chondrial dysfunction induced by hydrophobic
bile acids. In contrast, UDCA increased impair-
ment of mitochondrial function, which agrees
with the observed effects on hepatocytes in pri-
mary culture.
In fact, rather than cytoprotection, we observed
that UDCA caused synergistic cell killing by all
other bile acids. This then provides compelling
evidence that the reported improvement of bio-
chemical parameters in patients with cholestasis
does not reflect an interaction of the bile acids
directly on hepatocyte viability and must there-
fore reflect some other level of interaction, such as
membrane transport or non-parenchymal cell
function. Generation of bile flow is a regulated
process that depends on the coordinated action of
a number of transporter proteins in the sinusoidal
and canalicular domains of the hepatocyte. The
expression and function of these transport
proteins are known to be significantly altered
during cholestasis (Muller and Jansen, 1997).
Since UDCA enriches the bile in cholestatic pa-
tients receiving treatment (Lindor et al., 1998), a
preferential uptake of UDCA by the transporters
could explain the observed improvement in bio-
chemical indices (van Hoogstraten et al., 1999).
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